Detection of gene expression signatures related to underlying disease and treatment in rheumatoid arthritis patients

REFERENCES

• Lequerre T, Coulouarn C, Derambure C, Lefebvre G, Vittecoq 0, Daveau M, et al. A new tool for rheumatology: large-scale analysis of gene expression. Joint Bone Spine. 2003;70(4): 248–56.
   Google Scholar
• van Baarsen LG, Bos CL, van der Pouw Kraan TC, Verweij CL. Transcription profiling of rheumatic diseases. Arthr Res Ther 2009;11(1):207.
   PubMedGoogle Scholar
• Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signa-ture in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA. 2003;100(5):2610–5.
   PubMed Web of Science ®Google Scholar
• Crow MK, Kirou KA, Wohlgemuth J. Microanay analysis of interferon-regulated genes in SLE. Autoimmunity. 2003;36(8): 481–90.
   Google Scholar
• Lequerre T, Bansard C, Vittecoq 0, Derambure C, Hiron M, Daveau M, et al. Early and long-standing rheumatoid arthritis: distinct molecular signatures identified by gene-expression pro-filing in synovia. Arthr Res Ther. 2009;11(3):R99.
   Google Scholar
• Reynier F, Pachot A, Paye M, Xu Q, Tunel-Davin F, Petit F, et al. Specific gene expression signature associated with devel-opment of autoimmune type-I diabetes using whole-blood microanay analysis. Genes Immun. 2010;11(3):269–78.
   Google Scholar
• Bennett CN, Green JE. Genomic analyses as a guide to target identification and preclinical testing of mouse models of breast cancer. Toxicol Pathol. 2010;38(1):88–95.
   PubMed Web of Science ®Google Scholar
• Fayad W, Fryknas M, Brnjic S, Olofsson MH, Larsson R, Linder S. Identification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux transporters. PLoS One. 2009; 4(10):e7238.
   Web of Science ®Google Scholar
• Yao Y, Richman L, Higgs BW, Morehouse CA, de los Reyes M, Brohawn P, et al. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthr Rheum. 2009;60(6):1785–96.
   Google Scholar
• Kunz G. Use of a genomic test (MammaPrintTm) in daily clinical practice to assist in risk stratification of young breast cancer patients. Arch Gynecol Obstet. 2011;283(3):597–602.
   PubMed Web of Science ®Google Scholar
• Bansard C, Lequerre T, Daveau M, Boyer 0, Tron F, Salier JP, et al. Can rheumatoid arthritis responsiveness to methotrexate and biolo-gics be predicted? Rheumatology (Oxford). 2009;48(9):1021–8.
   PubMed Web of Science ®Google Scholar
• Koczan D, Drynda S, Hecker M, Drynda A, Guthke R, Kekow J, et al. Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept. Arthr Res Ther. 2008;10(3):R50.
   Web of Science ®Google Scholar
• Lequerre T, Gauthier-Jauneau AC, Bansard C, Derambure C, Hiron M, Vittecoq 0, et al. Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. Arthr Res Ther. 2006;8(4):R105.
   Google Scholar
• Sekiguchi N, Kawauchi S, Furuya T, Inaba N, Matsuda K, Ando S, et al. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab. Rheuma-tology (Oxford). 2008;47(6):780–8.
   PubMed Web of Science ®Google Scholar
• van Baarsen LG, Wijbrandts CA, Rustenburg F, Cantaert T, van der Pouw Kraan TC, Baeten DL, et al. Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. Arthr Res Ther. 2010;12(1):R11.
   Google Scholar
• van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Voskuyl AE, Rustenburg F, Baggen JM, et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis. 2007;66(8):1008–14.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthr Rheum. 1988;31(3):315–24.
   PubMed Web of Science ®Google Scholar
• Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthr Rheum. 1995;38(1):44–8.
   Google Scholar
• Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162(1):156–9.
   PubMed Web of Science ®Google Scholar
• Saeed AT, Sharov V, White J, Li J, Liang W, Bhagabati N, et al. TM4: a free, open-source system for microanay data manage-ment and analysis. Biotechniques. 2003;34(2):374–8.
   PubMed Web of Science ®Google Scholar
• Saeed AT, Bhagabati NK, Braisted JC, Liang W, Sharov V, Howe EA, et al. TM4 microarray software suite. Methods Enzymol. 2006;411:134–93.
   PubMed Web of Science ®Google Scholar
• Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5(10):R80.
   PubMed Web of Science ®Google Scholar
• Lleonart R, Naf D, Browning H, Weissmann C. A novel, quan-titative bioassay for type I interferon using a recombinant indi-cator cell line. Biotechnology (N Y). 1990;8(12):1263–7.
   PubMedGoogle Scholar
• Yao Y, Higgs BW, Richman L, White B, Jallal B. Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNalpha antibody, in systemic lupus erythematosus. Arthr Res 'Ther. 2010;12[Suppl 1]:S6.
   Google Scholar
• Bauer JW, Baechler EC, Petri M, Batliwalla FM, Crawford D, Ortmann WA, et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med. 2006;3(12):e491.
   PubMed Web of Science ®Google Scholar
• Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banche-reau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003;197(6):711–23.
   Google Scholar
• Crow MK. Type I. Interferon and autoimmune disease. Auto-immunity. 2003;36(8):445–6.
   Google Scholar
• Lyons PA, McKinney EF, Rayner TF, Hatton A, Woffendin HB, Koukoulaki M, et al. Novel expression signatures identified by transcriptional analysis of separated leucocyte subsets in systemic lupus erythematosus and vasculitis. Ann Rheum Dis. 2010;69(6): 1208–13.
   PubMed Web of Science ®Google Scholar
• Nikpour M, Dempsey AA, Urowitz MB, Gladman DD, Barnes DA. Association of a gene expression profile from whole blood with disease activity in systemic lupus erythaematosus. Ann Rheum Dis. 2008;67(8):1069–75.
   Google Scholar
• Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity. 2006; 25(3):383–92.
   PubMed Web of Science ®Google Scholar
• Bave U, Magnusson M, Eloranta ML, Perers A, Alm GV, Ron-nblom L. Fc gamma Rila is expressed on natural IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG. J Immunol. 2003;171(6):3296–302.
   Google Scholar
• Bave U, Nordmark G, Lovgren T, Ronnelid J, Cajander S, Elo-ranta ML, et al. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mecha-nism. Arthr Rheum. 2005;52(4):1185–95.
   Google Scholar
• Eloranta ML, Barbasso HS, Ulfgren AK, Ronnblom L, Alm GV, Lundberg IE. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthr Rheum. 2007;56(9): 3112–24.
   PubMedGoogle Scholar
• Lovgren T, Eloranta ML, Bave U, Alm GV, Ronnblom L. Induction of interferon-alpha production in plasmacytoid den-dritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthr Rheum. 2004;50(6):1861–72.
   Google Scholar
• van Holten J, Smeets TJ, Blankert P, Tak PP. Expression of interferon beta in synovial tissue from patients with rheumatoid arthritis: comparison with patients with osteoarthritis and reactive arthritis. Ann Rheum Dis. 2005;64(12):1780–2.
   PubMed Web of Science ®Google Scholar
• Thurlings RM, Boumans M, Tekstra J, van Roon JA, Vos K, van Westing DM, et al. Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum 2010;62(12):3607–14.
   PubMedGoogle Scholar
• Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA. 2005;102(9):3372–7.
   PubMed Web of Science ®Google Scholar
• Reynier F, Petit F, Paye M, Turrel-Davin F, Imbert PE, Hot A, et al. Importance of correlation between gene expression levels: application to the type I interferon signature in rheumatoid arthritis. PLoS One. 2011;6(10):e24828.
   Google Scholar
• Bienkowska JR, Dalgin GS, Batliwalla F, Allaire N, Roubenoff R, Gregersen PK, et al. Convergent random forest predictor: methodology for predicting drug response from genome-scale data applied to anti-TNF response. Genomics. 2009;94(6): 423–32.
   PubMed Web of Science ®Google Scholar
• Julia A, Erra A, Palacio C, Tomas C, Sans X, Barcelo P, et al. An eight-gene blood expression profile predicts the response to inf-fiximab in rheumatoid arthritis. PLoS One. 2009;4(10):e7556.
   Web of Science ®Google Scholar
• Feske S, Picard C, Fischer A. Immunodeficiency due to mutations in ORAI1 and STIM1. Clin Immunol. 2010;135(2):169–82.
   Google Scholar
• Khanna R, Chang MC, Joiner WJ, Kaczmarek LK, Schlichter LC. hSK4/hIK1, a calmodulin-binding KCa channel in human T lymphocytes. Roles in proliferation and volume regulation. J Biol Chem. 1999;274(21):14838–49.
   Google Scholar
• Tang X, Pan F, Xia G, Liao F, Ge R, Mei Y, et al. A single-nucleotide polymorphism marker within the FCRL5 gene and HLA-B27 positive Han Chinese ankylosing spondylitis patients. Tissue Antigens. 2009;74(4):314–6.
   PubMedGoogle Scholar
• Campbell JA, Davis RS, Lilly LM, Fremont DH, French AR, Carayannopoulos LN. Cutting edge: FcR-like 5 on innate B cells is targeted by a poxvirus MHC class I-like immunoevasin. J Immunol. 2010;185(1):28–32.
   PubMed Web of Science ®Google Scholar